Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

Oncologist

Volumn 19, Issue 4, 2014, Pages 318-327

  Muss, Hyman ^a   Cortes, Javier ^b   Vahdat, Linda T ^c   Cardoso, Fatima ^d   Twelves, Chris ^e   Wanders, Jantien ^f   Dutcus, Corina E ^g   Yang, Jay ^h   Seegobin, Seth ^f   O'Shaughnessy, Joyce ⁱ  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f EISAI CO LTD   (Japan)

^g EISAI INC   (United States)

^h NJS Associates Company   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Age; Chemotherapy; Eribulin mesylate; Metastatic breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; HORMONE RECEPTOR; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; KETONE;

ADULT; AGE; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST METASTASIS; BRONCHOPNEUMONIA; DIZZINESS; DRUG EFFICACY; DYSPNEA; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIFE EXPECTANCY; LUNG INFECTION; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VOMITING; AGING; BREAST NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MORTALITY; NEOPLASM METASTASIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FURANS; HUMANS; KETONES; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84898456463     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0282     Document Type: Article

References (32)

1. Breast cancer facts & figures 2011-2012. Available at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf. Accessed March 4, 2014.
2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.
3. SEER cancer statistics review, 1975-2008. Available at http://seer.cancer.gov/csr/1975_2008/. Accessed March 4, 2014.
4. Oostendorp L J, Stalmeier PF, Donders AR et al. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthrax cyclones and taxanes: Asystematic review. Lancet Oncol 2011;12:1053-1061.
5. Largillier R, Ferrero JM, Doyen J et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008;19:2012-2019.
6. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials. J Clin Oncol 2010;28:1958-1962.
7. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009;101:1174-1181.
8. Cashman J, Wright J, Ring A. The treatment of comorbidities in older patients with metastatic cancer. Support Care Cancer 2010;18:651-655.
9. Ring A. The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer. Crit Rev Oncol Hematol 2010;76:127-132.
10. Ring A, Reed M, Leonard R et al.The treatment of early breast cancer in women over the age of 70. Br J Cancer 2011;105:189-193.
11. Muss HB. Coming of age: Breast cancer in seniors. The Oncologist 2011;16(suppl 1):79-87.
12. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-1021.
13. Jordan MA, Kamath K, Manna T et al. The primary antimitoticmechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-1095.
14. Okouneva T, Azarenko O, Wilson L et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7: 2003-2011.
15. Smith JA, Wilson L, Azarenko O et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010; 49:1331-1337.
16. Kuznetsov G, Ten Dyke K, Yu MJ et al. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc AmAssoc Cancer Res 2007; 48:275.
17. Wozniak KM, Nomoto K, Lapidus RG et al. Comparison of neuropathy-inducing effects of eribulinmesylate, paclitaxel, and ixabepilone inmice. Cancer Res 2011;71:3952-3962.
18. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomized study. Lancet 2011;377:914-923.
19. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-2961.
20. Cortes J, Vahdat L, Blum JL et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28: 3922-3928.
21. Hurria A, Cirrincione CT, Muss HB et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011;29:1290-1296.
22. Bedard PL, Bernard-Marty C, Raimondi C et al. The role of capecitabine in the management of breast cancerinelderlypatients. J Geriatr Oncol 2011;2:72-81.
23. Muss HB, Busby-Whitehead J. Older women with breast cancer: Slowprogress, great opportunity, now is the time. J Clin Oncol 2011;29:4608-4610.
24. Smith BD, Jiang J, McLaughlin SS et al. Improvement in breast cancer outcomes over time: Are older womenmissing out? J Clin Oncol 2011;29: 4647-4653.
25. Bouchardy C, Rapiti E, Blagojevic S et al. Older female cancer patients: Importance, causes, and consequences of undertreatment. JClin Oncol 2007; 25:1858-1869.
26. Lavelle K, Todd C, Moran A et al. Nonstandard management of breast cancer increases with age in the UK: A population based cohort of women. or 565 years. Br J Cancer 2007;96: 1197-1203.
27. Lichtman SM, Hurria A, Cirrincione CT et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: Combined analysis of CALGB9342and9840. AnnOncol 2012;23:632-638.
28. Biganzoli L, Coleman R, Minisini A et al. Ajoined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 2007;61:84-89.
29. Blum JL, Kohles J, McKenna E et al. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat 2011;125:431-439.
30. Schneider M, Zuckerman IH, Onukwugha E et al. Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: A population-based analysis. J Am Geriatr Soc 2011;59:637-646.
31. Barni S, Cabiddu M, Petrelli F. Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: Benefits and pitfalls. Expert Rev Anticancer Ther 2010;10:185-198.
32. Marschner N, Dorfel S, Meyer D et al. Effectiveness of taxane- or anthracyline-based compared to taxane-and anthracyline-free first-line treatments of patients with metastatic breast cancer treated by German office-based medical oncologists. Data from theTMK registry group [abstract 41]. Breast 2013;22: S33.